Gut bacteria transplant trial aims to reboot cancer treatment
NCT ID NCT07432984
Summary
This study is testing whether a fecal microbiota transplant (FMT) can help a cancer immunotherapy drug work again for people with advanced non-small cell lung cancer. The treatment is for patients whose cancer has continued to grow despite previous immunotherapy. Researchers will give patients a transplant of gut bacteria from a healthy donor, along with the drug tislelizumab, to see if it can restore the immune system's ability to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.